Abstract
Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer patients receiving traditional chemotherapeutics or novel targeted drugs. Here, we developed a targeted nanoplatform based on biodegradable boronic acid modified ε-polylysine to co-deliver P-gp siRNA, Bcl-2 siRNA, and doxorubicin for overcoming the challenge. The targeted nanoplatform showed a robust suppressing efficiency for the invasion, proliferation, and colony formation of adriamycin (ADR) resistant breast cancer cell line (MCF-7/ADR) cells in vitro. The ATP responsiveness of the nanoplatform was also proved in the research. In the in vivo antitumor experiment, the targeted nanoplatform showed a significant inhibition of tumor growth with good biocompatibility. The goal of this study is to develop a novel and facile strategy to prepare a highly efficient and safe gene and drug delivery system for MDR breast cancer based on biocompatible ε-polylysine polymers.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
DeSantis, C.; Siegel, R.; Bandi, P.; Jemal, A. Breast cancer statistics, 2011. CA Cancer J. Clin. 2011, 61, 409–418.
Maughan, K. L.; Lutterbie, M. A.; Ham, P. S. Treatment of breast cancer. Am. Fam. Physician 2010, 81, 1339–1346.
Wang, H.; Mao, X. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des. Devel. Ther. 2020, 14, 2423–2433.
Fisusi, F. A.; Akala, E. O. Drug combinations in breast cancer therapy. Pharm. Nanotechnol. 2019, 7, 3–23.
Vaidya, J. S.; Massarut, S.; Vaidya, H. J.; Alexander, E. C.; Richards, T.; Caris, J. A.; Sirohi, B.; Tobias, J. S. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ 2018, 360, j5913.
Krug, D.; Loibl, S. Neoadjuvant chemotherapy for early breast cancer. Lancet Oncol. 2018, 19, e129.
Cazzaniga, M. E.; Dionisio, M. R.; Riva, F. Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett. 2017, 400, 252–258.
Cazzaniga, M. E.; Pinotti, G.; Montagna, E.; Amoroso, D.; Berardi, R.; Butera, A.; Cagossi, K.; Cavanna, L.; Ciccarese, M.; Cinieri, S. et al. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. Breast 2019, 48, 7–16.
Yuan, Y. L.; Cai, T. G.; Xia, X.; Zhang, R. H.; Chiba, P.; Cai, Y. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer. Drug Deliv. 2016, 23, 3350–3357.
Li, Y. L.; Gao, X. N.; Yu, Z. Z.; Liu, B.; Pan, W.; Li, N.; Tang, B. Reversing multidrug resistance by multiplexed gene silencing for enhanced breast cancer chemotherapy. ACS Appl. Mater. Interfaces 2018, 10, 15461–15466.
Doyle, L. A.; Yang, W. D.; Abruzzo, L. V.; Krogmann, T.; Gao, Y. M.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665–15670.
Chen, Z. L.; Shi, T. L.; Zhang, L.; Zhu, P. L.; Deng, M. Y.; Huang, C.; Hu, T. T.; Jiang, L.; Li, J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016, 370, 153–164.
Shi, X. L.; Dou, Y. H.; Zhou, K. R.; Huo, J. L.; Yang, T. J.; Qin, T. T.; Liu, W. H.; Wang, S. Q.; Yang, D. X.; Chang, L. M. et al. Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line. Biomed. Pharmacother. 2017, 90, 897–905.
Clarke, R.; Leonessa, F.; Trock, B. Multidrug resistance/P-glycoprotein and breast cancer: Review and meta-analysis. Semin. Oncol. 2005, 32, 9–15.
Risnayanti, C.; Jang, Y. S.; Lee, J. J.; Ahn, H. J. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Sci. Rep. 2018, 8, 7498.
Wu, Y.; Zhang, Y.; Zhang, W.; Sun, C. L.; Wu, J. Z.; Tang, J. H. Reversing of multidrug resistance breast cancer by co-delivery of Pgp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Colloids Surf. B Biointerfaces 2016, 138, 60–69.
Mello, C. C.; Conte, D. Jr. Revealing the world of RNA interference. Nature 2004, 431, 338–342.
Han, H. Y. RNA interference to knock down gene expression. Methods Mol. Biol. 2018, 1706, 293–302.
Liu, H. M.; Wang, H.; Yang, W. J.; Cheng, Y. Y. Disulfide cross-linked low generation dendrimers with high gene transfection efficacy, low cytotoxicity, and low cost. J. Am. Chem. Soc. 2012, 134, 17680–17687.
Shi, Y.; Lammers, T. Combining nanomedicine and immunotherapy. Acc. Chem. Res. 2019, 52, 1543–1554.
Shen, W. W.; Wang, Q. W.; Shen, Y.; Gao, X.; Li, L.; Yan, Y.; Wang, H.; Cheng, Y. Y. Green tea catechin dramatically promotes RNAi mediated by low-molecular-weight polymers. ACS Cent. Sci. 2018, 4, 1326–1333.
Yang, J. P.; Zhang, Q.; Chang, H.; Cheng, Y. Y. Surface-engineered dendrimers in gene delivery. Chem. Rev. 2015, 115, 5274–5300.
Wang, H.; Huang, Q.; Chang, H.; Xiao, J. R.; Cheng, Y. Y. Stimuli-responsive dendrimers in drug delivery. Biomater. Sci. 2016, 4, 375–390.
Lv, J.; Fan, Q. Q.; Wang, H.; Cheng, Y. Y. Polymers for cytosolic protein delivery. Biomaterials 2019, 218, 119358.
Wang, M. M.; Liu, H. M.; Li, L.; Cheng, Y. Y. A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios. Nat. Commun. 2014, 5, 3053.
Liu, H. M.; Wang, Y.; Wang, M. M.; Xiao, J. R.; Cheng, Y. Y. Fluorinated poly(propylenimine) dendrimers as gene vectors. Biomaterials 2014, 35, 5407–5413.
Shi, C.; He, Y.; Feng, X. B.; Fu, D. H. ε-Polylysine and next-generation dendrigraft poly-L-lysine: Chemistry, activity, and applications in biopharmaceuticals. J. Biomater. Sci. Polym. Ed. 2015, 26, 1343–1356.
Kim, S. W. Polylysine copolymers for gene delivery. Cold Spring Harb Protoc. 2012, 2012, 433–438.
Chen, H. C.; Tian, J. W.; Liu, D. Y.; He, W. J.; Guo, Z. J. Dual aptamer modified dendrigraft poly-L-lysine nanoparticles for overcoming multi-drug resistance through mitochondrial targeting. J. Mater. Chem. B 2017, 5, 972–979.
Kodama, Y.; Kuramoto, H.; Mieda, Y.; Muro, T.; Nakagawa, H.; Kurosaki, T.; Sakaguchi, M.; Nakamura, T.; Kitahara, T.; Sasaki, H. Application of biodegradable dendrigraft poly-L-lysine to a small interfering RNA delivery system. J. Drug Target. 2017, 25, 49–57.
Kodama, Y.; Nakamura, T.; Kurosaki, T.; Egashira, K.; Mine, T.; Nakagawa, H.; Muro, T.; Kitahara, T.; Higuchi, N.; Sasaki, H. Biodegradable nanoparticles composed of dendrigraft poly-L-lysine for gene delivery. Eur. J. Pharm. Biopharm. 2014, 87, 472–479.
Liu, Y.; Li, J. F.; Shao, K.; Huang, R. Q.; Ye, L. Y.; Lou, J. N.; Jiang, C. A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials 2010, 31, 5246–5257.
Cottet, H.; Martin, M.; Papillaud, A.; Souaïd, E.; Collet, H.; Commeyras, A. Determination of dendrigraft poly-L-lysine diffusion coefficients by taylor dispersion analysis. Biomacromolecules 2007, 8, 3235–3243.
Ryu, J. H.; Lee, G. J.; Shih, Y. R. V.; Kim, T. I.; Varghese, S. Phenylboronic acid-polymers for biomedical applications. Curr. Med. Chem. 2019, 26, 6797–6816.
Winblade, N. D.; Nikolic, I. D.; Hoffman, A. S.; Hubbell, J. A. Blocking adhesion to cell and tissue surfaces by the chemisorption of a poly-L-lysine-graft-(poly(ethylene glycol); phenylboronic acid) copolymer. Biomacromolecules 2000, 1, 523–533.
Peng, H. F.; Ning, X. Y.; Wei, G.; Wang, S. P.; Dai, G. L.; Ju, A. Q. The preparations of novel cellulose/phenylboronic acid composite intelligent bio-hydrogel and its glucose, pH-responsive behaviors. Carbohydr. Polym. 2018, 195, 349–355.
Ye, L.; Liu, H. M.; Fei, X.; Ma, D.; He, X. Z.; Tang, Q. Y.; Zhao, X.; Zou, H. B.; Chen, X. J.; Kong, X. M. et al. Enhanced endosomal escape of dendrigraft poly-L-lysine polymers for the efficient gene therapy of breast cancer. Nano Res. 2021, 15, 1135–1144.
Liu, C. Y.; Shao, N. M.; Wang, Y. T.; Cheng, Y. Y. Clustering small dendrimers into nanoaggregates for efficient DNA and siRNA delivery with minimal toxicity. Adv. Healthc. Mater. 2016, 5, 584–592.
Liu, H. M.; Chang, H.; Lv, J.; Jiang, C.; Li, Z. X.; Wang, F.; Wang, H.; Wang, M. M.; Liu, C. Y.; Wang, X. Y. et al. Screening of efficient siRNA carriers in a library of surface-engineered dendrimers. Sci. Rep. 2016, 6, 25069.
Liu, C. Y.; Wan, T.; Wang, H.; Zhang, S.; Ping, Y.; Cheng, Y. Y. A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci. Adv. 2019, 5, eaaw8922.
Abnous, K.; Danesh, N. M.; Ramezani, M.; Alibolandi, M.; Bahreyni, A.; Lavaee, P.; Moosavian, S. A.; Taghdisi, S. M. A smart ATP-responsive chemotherapy drug-free delivery system using a DNA nanostructure for synergistic treatment of breast cancer in vitro and in vivo. J. Drug Target. 2020, 28, 852–859.
Ma, D.; Liu, H. M.; Zhao, P. P.; Ye, L.; Zou, H. B.; Zhao, X.; Dai, H. L.; Kong, X. M.; Liu, P. F. Programing assembling/releasing multifunctional miRNA nanomedicine to treat prostate cancer. ACS Appl. Mater. Interfaces 2020, 12, 9032–9040.
Friedl, P.; Alexander, S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011, 147, 992–1009.
Paul, C. D.; Mistriotis, P.; Konstantopoulos, K. Cancer cell motility: Lessons from migration in confined spaces. Nat. Rev. Cancer 2017, 17, 131–140.
Mattheolabakis, G.; Milane, L.; Singh, A.; Amiji, M. M. Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine. J. Drug Target. 2015, 23, 605–618.
Acknowledgements
The authors take the grants from the National Natural Science Foundation of China (Nos. 81771968, 82003166, and 21704061), the Natural Science Foundation of Shanghai (No. 21ZR1439200), Shanghai Sailing Program (No. 17YF1411000), Shanghai Municipal Education Commission-Gaofeng Clinical Grant Support (No. 20181705), Shanghai Municipal Commission of Health and Family Planning (No. 201840020), and the Medical-Engineering Joint Funds from the Shanghai Jiao Tong University (Nos. ZH2018ZDA05 and YG2016QN54) on this work.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
12274_2022_4254_MOESM1_ESM.pdf
A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer
Rights and permissions
About this article
Cite this article
Liu, H., Ma, D., Chen, J. et al. A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer. Nano Res. 15, 6306–6314 (2022). https://doi.org/10.1007/s12274-022-4254-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12274-022-4254-1